We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04237584
Recruitment Status : Terminated (The study was stopped due to insurmountable enrollment challenges affecting trial accrual, resulting from the rapidly evolving treatment options for advanced prostate cancer.)
First Posted : January 23, 2020
Last Update Posted : April 8, 2022
Sponsor:
Collaborators:
Bayer
Carolina Urologic Research Center
Tulane University
Barbara Ann Karmanos Cancer Institute
Information provided by (Responsible Party):
MANA RBM

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Terminated
Actual Primary Completion Date : March 7, 2022
Actual Study Completion Date : March 7, 2022
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 May 23, 2022
June 16, 2022 Submission with QC Comments
2 July 22, 2022
August 15, 2022 Submission with QC Comments
3 September 9, 2022